MEDICINES FOR EUROPE
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
MEDICINES FOR EUROPE has 173 disclosed EU lobbying meetings from 2019-05-07 to 2026-10-22: 94 with the European Commission and 79 with Members of the European Parliament. Source: EU Transparency Register no. 48325781850-28, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2026-05-12- Category
- Trade and business associations
- Legal status
- AISBL
- Declared lobbying cost
- €500,000
- Lobbying FTEs
- 7.95
- Members
- 4
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Budget · Business and industry · Climate action · Communication · Competition · Consumers · Customs · Digital economy and society · Economy, finance and the euro · Education and training · Employment and social affairs · Enlargement
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Stella Kyriakides17
- Olivér Várhelyi7
- Karolina Herbout-Borczak6
- Thierry Breton6
- Maurits-Jan Prinz5
Disclosed meetings
Newest first, showing the most recent 60 of 173. EC = European Commission, EP = Member of the European Parliament.
- European Biotech Act and the Generic and Biosimilar Medicines Sectorsource ↗
- Biotech Actsource ↗
- Biosimilar pharmaceutical policysource ↗
- 2026-07-09ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiSustainability of European pharmaceutical manufacturingsource ↗
- 2026-07-09ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiSustainability of European pharmaceutical manufacturingsource ↗
- 2026-07-08ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiPreventive health and early detectionsource ↗
- Biotechsource ↗
- Biotech Actsource ↗
- Politique industrielle européennesource ↗
- Biotech Actsource ↗
- Innovation policysource ↗
- Biosimilar Medicines, Access to Healthcare and EU Biotech Competitivenesssource ↗
- Exchange of views on Biotech Actsource ↗
- European Biotech Actsource ↗
- Competitiveness of the Biotech Sectorsource ↗
- Biotech Act Isource ↗
- Biotech actsource ↗
- UWWTD and BioTech Actsource ↗
- 2026-06-10ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- avloppsdirektivetsource ↗
- Biotech Actsource ↗
- 2026-05-04ECOlga Solomon · Head of Unit- challenges for generic and biosimilar applicants in accessing reference products - clear guidelines on use of reference data for ERAsource ↗
- Urban Wastewater Treatment Directivesource ↗
- Biotech Actsource ↗
- 2026-04-16ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECKatri Teedumäe · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- UWWTD Resolutionsource ↗
- EU Biotech Act Isource ↗
- Urban Waste Water Directivesource ↗
- 2026-03-25ECPaula Duarte Gaspar · Head of UnitExtended Producer Responsibility under the recast Urban Wastewater Treatment Directivesource ↗
- Exchange of views on Biotech Actsource ↗
- 2026-03-17ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiCurrent pharma matterssource ↗
- SANT Committeesource ↗
- 2026-03-16ECGiulia Del Brenna · Head of UnitSubject matters relevant to the pharmaceutical industry in particular those in which DG GROW is involved.source ↗
- Critical medicines actsource ↗
- EU Biotech Actsource ↗
- pharmaceutical policysource ↗
- The Critical Medicines Act and the Future of Access to Essential Medicines in the EUsource ↗
- Biotech, UWWTDsource ↗
- 2026-03-04ECPernille Weiss-Ehler · Cabinet of Commissioner Jessika RoswallUWWTD- the Urban Wastewater Treatment Directivesource ↗
- 2026-02-24ECUlla Schwager · Head of UnitRecent policy developments concerning the pharmaceutical industriessource ↗
- 2026-02-17ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiBiotech Act, Pharma package, CMAsource ↗
- 2026-02-09ECOlivier Girard · Head of UnitExchange of views on health security, civ-mil cooperation and competitiveness considering the current geopolitical situation.source ↗
- Exchange of views on Cardiovascular Strategysource ↗
- CMA + Health policysource ↗
- Urban Waste Water Treatment Directivesource ↗
- 2026-01-16ECPatrick Child · Deputy Director-GeneralPFAS letter /UWWT studysource ↗
- Health Policysource ↗
- 2026-01-12ECRainer Becker · DirectorThe meeting took place upon request of MfE to discuss a PFAS restriction under REACH, the Urban Waste Water Treatment Directive (UWWTD), the Biotech Act and the Critical Medicines Act (CMA)source ↗
- Review of the EU General Pharmaceutical Legislationsource ↗
Frequently asked
How many EU lobbying meetings has MEDICINES FOR EUROPE disclosed?
MEDICINES FOR EUROPE (EU Transparency Register no. 48325781850-28) appears in 173 disclosed meetings with EU officials and MEPs between 2019-05-07 and 2026-10-22: 94 with the European Commission and 79 with Members of the European Parliament.
What does MEDICINES FOR EUROPE lobby on?
MEDICINES FOR EUROPE's disclosed EU meetings most often concern Health, Technology, Trade, Industry. Every meeting and its topic is listed with its official source on this page.
Who does MEDICINES FOR EUROPE meet in Brussels?
Across its disclosed meetings, MEDICINES FOR EUROPE has met Commission officials including Stella Kyriakides, Olivér Várhelyi, Karolina Herbout-Borczak, and MEPs including VERYGA Aurelijus, KNOTEK Ondřej, METZ Tilly. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with MEDICINES FOR EUROPE — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.